User profiles for Sergio Vano-Galvan

Sergio Vañó-Galván

Director of Trichology Unit #TricoHRC, Dermatology Service, Ramon y Cajal Hospital …
Verified email at uah.es
Cited by 6367

Safety of low‐dose oral minoxidil treatment for hair loss. A systematic review and pooled‐analysis of individual patient data

J Jimenez‐Cauhe, D Saceda‐Corralo… - Dermatologic …, 2020 - Wiley Online Library
low dose oral minoxidil (OM) is an increasingly used treatment for androgenetic alopecia and
other types of hair loss. to analyze available data of patients treated with OM, focusing on …

In situ production of ROS in the skin by photodynamic therapy as a powerful tool in clinical dermatology

P Fonda-Pascual, OM Moreno-Arrones… - Methods, 2016 - Elsevier
Photodynamic therapy (PDT) is a clinical modality of photochemotherapy based on the
accumulation of a photosensitizer in target cells and subsequent irradiation of the tissue with light …

[PDF][PDF] A preliminary observation: Male pattern hair loss among hospitalized COVID-19 patients in Spain-A potential clue to the role of androgens in COVID-19 severity

A Goren, S Vano-Galvan… - J Cosmet …, 2020 - minerva-access.unimelb.edu.au
A preliminary observation of high frequency of male pattern hair loss among admitted COVID-19
patients, and suggest that androgen expression might be a clue to COVID-19 severity. …

Androgen sensitivity gateway to COVID‐19 disease severity

CG Wambier, A Goren, S Vaño‐Galván… - Drug development …, 2020 - Wiley Online Library
In this communication, we present arguments for androgen sensitivity as a likely determinant
of COVID‐19 disease severity. The androgen sensitivity model explains why males are …

[HTML][HTML] Racial variations in COVID‐19 deaths may be due to androgen receptor genetic variants associated with prostate cancer and androgenetic alopecia. Are anti …

J McCoy, CG Wambier, S VanoGalvan… - Journal of cosmetic …, 2020 - ncbi.nlm.nih.gov
Dear Editor, As the SARS-CoV-2 (COVID-19) pandemic continues to infect many more
Americans, a racial disparity in the number of deaths from infection has emerged. On April 7, 2020…

Safety of low-dose oral minoxidil for hair loss: a multicenter study of 1404 patients

S Vañó-Galván, R Pirmez, A Hermosa-Gelbard… - Journal of the American …, 2021 - Elsevier
Background The major concern regarding the use of low-dose oral minoxidil (LDOM) for the
treatment of hair loss is the potential risk of systemic adverse effects. Objective To describe …

[HTML][HTML] Treatments for moderate-to-severe alopecia areata: a systematic narrative review

A Egeberg, L Linsell, E Johansson, F Durand… - Dermatology and …, 2023 - Springer
Treatments for alopecia areata (AA) have traditionally been prescribed off-label, and there
has been no universal agreement on how to best manage the condition. Baricitinib is the first …

[HTML][HTML] Trichodynia and telogen effluvium in COVID-19 patients: Results of an international expert opinion survey on diagnosis and management

…, T Silyuk, R Sinclair, A Tosti, S Vano-Galvan… - JAAD international, 2021 - Elsevier
Background The cutaneous manifestations of COVID-19 may be useful disease markers and
prognostic indicators. Recently, postinfectious telogen effluvium and trichodynia have also …

[HTML][HTML] What does androgenetic alopecia have to do with COVID‐19? An insight into a potential new therapy

…, J McCoy, CG Wambier, S VanoGalvan… - Dermatologic …, 2020 - ncbi.nlm.nih.gov
FIGURE 1 TMPRSS2 gene transcription promoter site requires an activated androgen
receptor, with androgens such as testosterone. Dihydrotestosterone (DHT) a potent androgen …

[HTML][HTML] Proxalutamide reduces the rate of hospitalization for COVID-19 male outpatients: a randomized double-blinded placebo-controlled trial

J McCoy, A Goren, FA Cadegiani… - Frontiers in …, 2021 - ncbi.nlm.nih.gov
Antiandrogens have demonstrated a protective effect for COVOD-19 patients in observational
and interventional studies. The goal of this study was to determine if proxalutamide, an …